2025 H2 -tulosraportti
122 päivää sitten
‧38 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·14 t sittenI have a question. Is AlphaOne only a Pb-212 factory? Or can the facility also produce Th-228 and Ra-224 if the market changes? I see AlphaOne as a possible production platform, not just one isotope. Do you agree, or am I overlooking something? Do you see other possibilities?
The factory primarily produces Th-228, and that's what they have most delivery agreements for. It's not practical to deliver Pb-212 due to a short half-life of approx 10h. In that case, the treatment clinic must be located near production. They only have delivery of Pb-212 to one Norwegian company as far as I know. Read up on stock exchange announcements. You'll find everything there.
·1 päivä sittenThor Medical – Perhaps one of the most exciting industrial cases on the Oslo Stock Exchange? ☢️🚀 I believe Thor Medical has a potential that is still not fully reflected in the market. The company is in the process of building a position in the production of radioisotopes – a market that is expected to grow strongly in the coming years. These are the triggers I'm following: ☢️ Startup of AlphaOne Perhaps the most important milestone. When production starts as planned, the company will go from building capacity to delivering products. 🏥 Increasing demand for radioisotopes The use of targeted cancer treatment is growing rapidly internationally. If this development continues, the demand for Thor Medical's products could increase significantly. 🤝 New customer agreements Long-term agreements with pharmaceutical companies or radiopharmaceutical producers will be a strong confirmation of both the technology and the business model. 🌍 European supplier The need for secure and stable supply chains has become more important. Thor Medical could gain an attractive position as a European producer in a market with increasing demand. 📈 Scaling and profitability When production capacity is better utilized, revenues can grow while a larger portion of costs are distributed over higher volume. 💊 A market in strong growth Personalized cancer treatment is one of the most exciting areas in medicine. If Thor Medical manages to establish itself as an important supplier, I believe the company could have a very interesting journey in the coming years. Of course, there is risk. Production startup, commercialization, and customer growth must be delivered as planned. But if the company reaches the most important milestones, I believe today's valuation could look completely different in a few years. I am long-term invested and look forward to the next announcements from the company. Not investment advice – just my own thoughts as a shareholder. ☢️📈
·2 päivää sittenQuite alright. I'm not fully loaded yet. Bottom fishing throughout the summer, can tolerate a few months.
·2 päivää sittenCalm down. Thor has delivered on what they have said (and promised) all along. building of the factory, comissioning of the production facility, ... They have a strong order book, ... They have said that commercial production will start in Q3 - we are at the end of Q2!! Have a good holiday and wait for a nice journey to hgøsten :-)
Absolutely, absolutely true! Autumn is coming, the key dates are lining up. The wait is almost over.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
122 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·14 t sittenI have a question. Is AlphaOne only a Pb-212 factory? Or can the facility also produce Th-228 and Ra-224 if the market changes? I see AlphaOne as a possible production platform, not just one isotope. Do you agree, or am I overlooking something? Do you see other possibilities?The factory primarily produces Th-228, and that's what they have most delivery agreements for. It's not practical to deliver Pb-212 due to a short half-life of approx 10h. In that case, the treatment clinic must be located near production. They only have delivery of Pb-212 to one Norwegian company as far as I know. Read up on stock exchange announcements. You'll find everything there.
- ·1 päivä sittenThor Medical – Perhaps one of the most exciting industrial cases on the Oslo Stock Exchange? ☢️🚀 I believe Thor Medical has a potential that is still not fully reflected in the market. The company is in the process of building a position in the production of radioisotopes – a market that is expected to grow strongly in the coming years. These are the triggers I'm following: ☢️ Startup of AlphaOne Perhaps the most important milestone. When production starts as planned, the company will go from building capacity to delivering products. 🏥 Increasing demand for radioisotopes The use of targeted cancer treatment is growing rapidly internationally. If this development continues, the demand for Thor Medical's products could increase significantly. 🤝 New customer agreements Long-term agreements with pharmaceutical companies or radiopharmaceutical producers will be a strong confirmation of both the technology and the business model. 🌍 European supplier The need for secure and stable supply chains has become more important. Thor Medical could gain an attractive position as a European producer in a market with increasing demand. 📈 Scaling and profitability When production capacity is better utilized, revenues can grow while a larger portion of costs are distributed over higher volume. 💊 A market in strong growth Personalized cancer treatment is one of the most exciting areas in medicine. If Thor Medical manages to establish itself as an important supplier, I believe the company could have a very interesting journey in the coming years. Of course, there is risk. Production startup, commercialization, and customer growth must be delivered as planned. But if the company reaches the most important milestones, I believe today's valuation could look completely different in a few years. I am long-term invested and look forward to the next announcements from the company. Not investment advice – just my own thoughts as a shareholder. ☢️📈
- ·2 päivää sittenQuite alright. I'm not fully loaded yet. Bottom fishing throughout the summer, can tolerate a few months.
- ·2 päivää sittenCalm down. Thor has delivered on what they have said (and promised) all along. building of the factory, comissioning of the production facility, ... They have a strong order book, ... They have said that commercial production will start in Q3 - we are at the end of Q2!! Have a good holiday and wait for a nice journey to hgøsten :-)Absolutely, absolutely true! Autumn is coming, the key dates are lining up. The wait is almost over.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
2025 H2 -tulosraportti
122 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·14 t sittenI have a question. Is AlphaOne only a Pb-212 factory? Or can the facility also produce Th-228 and Ra-224 if the market changes? I see AlphaOne as a possible production platform, not just one isotope. Do you agree, or am I overlooking something? Do you see other possibilities?The factory primarily produces Th-228, and that's what they have most delivery agreements for. It's not practical to deliver Pb-212 due to a short half-life of approx 10h. In that case, the treatment clinic must be located near production. They only have delivery of Pb-212 to one Norwegian company as far as I know. Read up on stock exchange announcements. You'll find everything there.
- ·1 päivä sittenThor Medical – Perhaps one of the most exciting industrial cases on the Oslo Stock Exchange? ☢️🚀 I believe Thor Medical has a potential that is still not fully reflected in the market. The company is in the process of building a position in the production of radioisotopes – a market that is expected to grow strongly in the coming years. These are the triggers I'm following: ☢️ Startup of AlphaOne Perhaps the most important milestone. When production starts as planned, the company will go from building capacity to delivering products. 🏥 Increasing demand for radioisotopes The use of targeted cancer treatment is growing rapidly internationally. If this development continues, the demand for Thor Medical's products could increase significantly. 🤝 New customer agreements Long-term agreements with pharmaceutical companies or radiopharmaceutical producers will be a strong confirmation of both the technology and the business model. 🌍 European supplier The need for secure and stable supply chains has become more important. Thor Medical could gain an attractive position as a European producer in a market with increasing demand. 📈 Scaling and profitability When production capacity is better utilized, revenues can grow while a larger portion of costs are distributed over higher volume. 💊 A market in strong growth Personalized cancer treatment is one of the most exciting areas in medicine. If Thor Medical manages to establish itself as an important supplier, I believe the company could have a very interesting journey in the coming years. Of course, there is risk. Production startup, commercialization, and customer growth must be delivered as planned. But if the company reaches the most important milestones, I believe today's valuation could look completely different in a few years. I am long-term invested and look forward to the next announcements from the company. Not investment advice – just my own thoughts as a shareholder. ☢️📈
- ·2 päivää sittenQuite alright. I'm not fully loaded yet. Bottom fishing throughout the summer, can tolerate a few months.
- ·2 päivää sittenCalm down. Thor has delivered on what they have said (and promised) all along. building of the factory, comissioning of the production facility, ... They have a strong order book, ... They have said that commercial production will start in Q3 - we are at the end of Q2!! Have a good holiday and wait for a nice journey to hgøsten :-)Absolutely, absolutely true! Autumn is coming, the key dates are lining up. The wait is almost over.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt